tbuckley/cabot-search huggingface dataset:
Association between geriatric assessment findings and clinical depression in 1092 older patients with cancer: The ELCAPA Cohort study.
Authors: Christophe Tournigand, Florence Canoui-Poitrine, Nicoleta Reinald, Marie Laurent, Esther Guery, Philippe Caillet, Jean-Philippe David, Jean-Leon Lagrange, Sylvie Bastuji-Garin, Cedric Lemogne, Elena Paillaud
Journal: Journal of Clinical Oncology (2015)

1574 Background: Few studies assessed jointlygeriatric and oncological factors associated with clinical depression in geriatric oncology setting. To assess the prevalence and associated factors of clinical depression in older patients with cancer. Methods: We studied a prospective cohort of cancer patients aged ≥ 70 years and referred to geriatric oncology clinics between 2007 and 2012. A multidimensional geriatric assessment (GA) was performed before treatment. Clinical depression was diagnosed by senior geriatricians by a semi-structured interview. It encompassed criteria of the Diagnostic and Statistical Manual of Mental Disorders (4th edition, DSM-IV) and of the International Classification of Diseases (10thedition, ICD-10). Multivariate analysis was based on multivariate logistic models. Systematic adjustement for gender was done. Results: Of 1121 consecutive patients, 1092 had available data (mean age, 80.4 years; women, 48.8%; metastases, 51.3%; cancer location: colorectal 21.1%, breast 16.8%, kidney bladder or urinary tract 14.0%, and prostate 11.4%). The overall prevalence of clinical depression was 28.4% (95% confidence interval, 25.7-31.2). Factors independently associated with clinical depression by multivariate analysis adjusting for all following factors and gender were impaired mobility (adjusted OR [aOR], 2.41; 1.64-3.54), impaired functional status defined as ECOG-PS ≥ 2 (aOR, 2.42; 1.83-3.76), inpatient status (aOR, 1.66; 1.18-2.32), metastatic status (aOR, 1.42; 1.01-2.01), inadequate social support (aOR, 1.58; 1.11-2.25), cognitive impairment (aOR, 1.73; 1.23-2.43), polypharmacy defined as five or more nonantidepressant drugs (aOR, 1.70; 1.18-2.44), and multimorbidity (aORadditional CIRS-G point, 1.07; 1.04-1.11). Conclusions: In older patients with cancer at various sites and stages, clinical depression was highly prevalent. Clinical depression was independently associated with several GA findings (impaired mobility and function, inadequate social support, cognitive impairment, polypharmacy, and multimorbidity) independently from with gender, tumor site, and metastatic status.
<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Authors: Meta Diekstra, Jesse J Swen, Epie Boven, Daniel E. Castellano, Hans Gelderblom, Ron H.J. Mathijssen, Cristina Rodriguez-Antona, Jesús García-Donas, Brian I. Rini, Henk-jan Guchelaar
Journal: Journal of Clinical Oncology (2015)

4548 Background: In our exploratory studies we have associated single nucleotide polymorphisms (SNPs) in candidate genes with efficacy and toxicities of sunitinib in metastatic renal cell carcinoma (mRCC). The aim of the present study is to test these SNPs for association with sunitinib treatment outcome in the largest patient cohort to date. Methods: mRCC patients treated with sunitinib and a DNA sample available were pooled from 3 exploratory studies conducted in the US, Spain and the Netherlands. A total of 22 SNPs and 6 haplotypes in 10 candidate genes related to pharmacokinetics and pharmacodynamics of sunitinib were tested for associations with toxicity, dose reductions, progression-free survival (PFS), overall survival (OS) and best objective response. Results: Three-hundred and thirty-three patients were included. The presence of CYP3A5*1 was associated with dose reductions (OR = 2.0, CI = 1.0-4.0, P= 0.039). Presence of CGT in the ABCB1 haplotype was associated with an increased PFS (HR = 1.9, CI = 1.3-2.6, P= 0.000275) and remained significant after Bonferroni correction. These associations are consistent with prior observations. Similar size and direction of effect were observed for the association of VEGFA rs1570360 with hypertension (OR = 1.9, CI = 0.8-4.5, P= 0.173) and FLT3 rs1933437 with leukopenia (OR = 3.6, CI = 0.8-16.7, P= 0.088). Conclusions: The confirmation of previously reported associations between polymorphisms in CYP3A5 and ABCB1 with sunitinib toxicity and efficacy respectively indicates that genotyping of these genetic variants may be useful for guiding sunitinib treatment.
Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.
Authors: David Samuel DiCapua Siegel, Thomas Martin, Seema Singhal, Michael Wang, Ravi Vij, Andrzej J. Jakubowiak, Sundar Jagannath, Sagar Lonial, Vishal Kukreti, Nizar J. Bahlis, Melissa Alsina, Asher Alban Akmal Chanan-Khan, Francis Buadi, Frederic J. Reu, George Somlo, Lori A. Kunkel, Kanya Rajangam, Yu-Lin Chang, Robert Z. Orlowski, A. Keith Stewart
Journal: Journal of Clinical Oncology (2012)

8035 Background: Patients (pts) with relapsed and refractory multiple myeloma (RR MM) who are refractory or intolerant to both bortezomib (BTZ) and immunomodulators (IMiDs; thalidomide [Thal] or lenalidomide [Len]) (ie, “double-refractory/intolerant”), have few therapeutic options and a poor prognosis. Carfilzomib (CFZ), a next generation proteasome inhibitor (PI), has shown durable single-agent activity in clinical studies including 003-A1, an open-label, single-arm phase 2b trial in RR MM. The present analysis describes clinical activity in pts from 003-A1 with double-refractory/intolerant disease and in other groups of clinical interest including pts with disease refractory to all 5 approved classes of anti-MM tx (alkylators, anthracyclines, corticosteroids, IMiDs, and PIs) in clinical use (“refractory to all approved tx”). Methods: Pts from 003-A1 with double-refractory/intolerant disease were analyzed, as were pts with disease refractory to all approved tx. CFZ was given on days 1, 2, 8, 9, 15, 16 of 28-day cycles (C), (20 mg/m 2 in C1; 27 mg/m 2 in C2–12). Primary endpoint was overall response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival, and safety. Results: The study ORR was 22.9% with median DOR of 7.8 mo (N=266). 228 pts (86%) with double-refractory/intolerant disease had ORRs of 20.6% and a median DOR of 7.4 mo. Conclusions: Single-agent CFZ demonstrated clinically meaningful, durable responses in pts with double-refractory/intolerant MM or disease refractory to all 5 approved classes of tx. The ORRs across groups of clinical interest were generally consistent with results for the entire study population. These results are notable for a next-generation PI and demonstrate the activity of single-agent CFZ in pts with advanced stage MM. [Table: see text]
Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study
Authors: Elsayed Z. Soliman, Jye-Yu C. Backlund, Ionut Bebu, Trevor J. Orchard, Bernard Zinman, John M. Lachin
Journal: Diabetes Care (2017)

We examined the association between the prevalence and incidence of electrocardiographic (ECG) abnormalities and the development of cardiovascular disease (CVD) in patients with type 1 diabetes, among whom these ECG abnormalities are common.
TRANSCATHETER VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN DIABETES MELLITUS: FROM THE NATIONWIDE INPATIENT SAMPLE
Authors: Tomo Ando, Emmanuel Akintoye, Tesfaye Telila, Alexandros Briasoulis, Hisato Takagi, David Slovut, Theodore Schreiber, Cindy Grines, Luis Afonso
Journal: Journal of the American College of Cardiology (2017)
Pharmacodynamic (PD) analyses of asparagine (Asn) deamination by asparaginases (ASNase) in cerebrospinal fluid (CSF) and in serum of pediatric standard risk acute lymphoblastic leukemia (SR ALL) patients (CCG-1962)
Authors: V. I. Avramis, E. H. Panosyan, C. H. Fu, J. S. Holcenberg
Journal: Journal of Clinical Oncology (2004)

8556 Background. Recent reports demonstrated the incomplete Asn depletion in CSF (Appel et al., Leukemia, 2003), which verified our earlier findings (Avramis et al., Blood 2002). Methods. We examined the measured by HPLC amino acid assay CSF and concomitant serum Asn deamination in 20 out of 24 relapsed plus 28 randomly selected event-free (CCR) patients (pts) from CCG-1962 SR ALL study. Results. These analyses are shown below. Asn levels in CSF or serum are lower significantly in both arms after ASNase treatment, however neither ASNase formulation resulted in complete Asn depletion in these biological fluids. In addition, specific PD analyses were conducted to evaluate the impact of the Input of Asn in the PEG-ASNase arm pts, characterized by the biochemical parameters of Imax plus additive error from the host, i.e., nutrients & the de-novo biosynthesis by the liver. The Imax of Asn in serum was estimated to be statistically higher in pts with events (8.9E-3 ±6E-3 nmoles/ml/min), than in the randomly selected CCR pts (PEG-ASNase arm) (1.3E-5 ±2.5E-5 nmoles/ml/min) p=0.002. Similarly, the E. coli ASNase arm pts had a lower Input in the CCR vs. the event pts. However, the additive rate of Input was not statistically different in the sub-groups of pts (2.9E-6 ±3.1E-6 for events & 2.2E-6 ±3.4E-6 nmoles/ml/min for CCR). These ASNase formulations administered at 2500 IU/ml PEG-ASNase x1 vs. 6000 IU/ml native ASNase × 9 doses resulted in non-statistically different deamination of Asn in serum during induction. Thus, there may not be a significant advantage of PEG over native ASNase in SR ALL. Conclusions. The Asn levels after Tx are similar in both arms in pts with events and CCR. Nevertheless the PD model suggests that there may be a higher contribution of Input of Asn in the relapsed in either arm than CCR pts. No significant financial relationships to disclose.
Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer
Authors: M. S. Rubin, J. Barton, D. Shipley, E. Arrowsmith, N. Peacock, L. Hart, J. Evans, E. Vasquez, H. A. Burris, D. A. Yardley
Journal: Journal of Clinical Oncology (2009)

1091 Background: Estrogen modulates angiogenesis via effects on endothelial cells with subsequent induction of vascular endothelial growth factor (VEGF). VEGF promotes tumor growth and is associated with poor response to antiestrogen therapy. This trial was designed to evaluate the progression-free survival (PFS) of bevacizumab (B) in combination with anastrozole (A) or fulvestrant (F) as first-line endocrine therapy (ET) in metastatic breast cancer (MBC). Methods: Eligibility criteria: no prior hormonal or chemotherapy for MBC, measurable or evaluable disease, normal LVEF, post-menopausal. Treatment: Arm A: anastrozole 1 mg po QD in pts who were a) ET naïve, b) ≥ 12 months from adjuvant ET, and c) intolerant of or progressed on prior tamoxifen. Arm B: fulvestrant 500 mg D1 and 250 mg D15 IM loading dose followed by 250 mg q28 days in pts who were a) &lt; 12 months from adjuvant aromatase inhibitors (AIs), b) intolerant of or progressed on AIs, and c) MD's discretion. Bevacizumab 10 mg/kg IV D1 q2 weeks was given in both arms. Trastuzumab permitted in HER-2+ pts only. Response assessments were q8 weeks; pts were treated until disease progression or toxicity. Results: 79 pts were enrolled fromNovember 2006 to November 2008. 42 pts are evaluable for response and toxicity, Arm A - 25 pts and Arm B - 17 pts. Median age was 64, ECOG PS 0 - 55%, 1- 43 %, adjuvant chemo 27%, adjuvant hormonal -38%, hormone receptor status: ER+/PR+ 80%, ER+/PR- 14%, ER-/PR+ 2 %. HER-2+ 5 pts, 31% had ≥ 2 metastatic disease sites predominately lung and bone only disease - 40%. Median # cycles - 4. 24% achieved a partial response and 57% stable disease; 7 pts progressed. G3 hypertension (12%) was the most common toxicity. Median PFS for Arm A was 16.3 months and has not yet been reached for Arm B. Conclusions: Bevacizumab in combination with anastrozole or fulvestrant is feasible and well tolerated with no unanticipated toxicities. The addition of bevacizumab resulted in prolongation of the median PFS to16.3 months with anastrozole as compared to the 7–9 month historical control PFS reported for first-line AI monotherapy in MBC. Further evaluation of bevacizumab endocrine combinations is warranted. [Table: see text]
SEX DIFFERENCES IN OUTCOMES AFTER STENTING OR BYPASS SURGERY FOR UNPROTECTED LEFT MAIN DISEASE
Authors: Gregg W. Stone, Rafael Cavalcante, Ari P. Kappetein, Joseph Sabik, Adrian Banning, David Taggart, Manel Sabate, Jose Polmar, Piet Boonstra, Nicholas Lembo, Charles Simonton, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2017)
Development of High Throughput PCR-Invader Assay to Detect the JAK2 V617F Mutation in Japanese Myeloproliferative Disorders
Authors: Yoshitaka Miyakawa, Makoto Suzuki, Toshikazu Yamaguchi, Kenji Yokoyama, Michiko Miyakawa, Yasuo Ikeda, Shinichiro Okamoto
Journal: Blood (2008)
Discovery of targetable genetic alterations in advanced non-small cell lunge cancer using next generation sequencing-based circulating tumor DNA assay.
Authors: Helei Hou, Xiaochun Zhang, Chuantao Zhang, Yanfang Guan, Dong Liu, Rongjiao Wang, Zhuokun Li, Yi Xin, Shiying Xuan
Journal: Journal of Clinical Oncology (2015)

e12500 Background: Analysis of ctDNA has the potential to revolutionize detection and monitoring of tumors. It’s difficult to identify tumor driving genes in advanced non small cell lung carcinoma (NSCLC) patients especially for those who were unable to obtain cancer tissue samples and had developed treatment resistance. The aim of this study was to discover actionable genomic alterations using next generation sequencing (NGS) based circulating tumor DNA (ctDNA) assay in advanced NSCLC patients so that approved drugs or investigational agents in clinical trials could be selected. Methods: 65 advanced NSCLC patients were enrolled and plasma samples were collected after informed consent provided by all patients. 7708 exons of 508 tumor related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, indels, copy number alterations, and gene fusions. The average median sequencing depth was 940×. Results: ctDNA somatic mutations were detected in 100% of patients. 15.4% (10/65) could select NCCN guideline approved targeted drugs according to the identified actionable genetic alterations (8EGFR mutation, 1EML4-ALK, 1KIF5B-RET). Our sequencing assay also identified a genomic alteration with targeted agents available in clinical trials in an additional 13.8% (9/65), which included anti-HER2 agents, mTOR inhibitors, CDK4/6 inhibitors, and K-ras mutation targeted agents. Conclusions: 29.2% (19/65) of advanced NSCLC patients harbored at least one actionable genetic alteration identified by noninvasive assay of ctDNA. NGS based targetable alterations detection in ctDNA might optimize personalized target therapy for advanced malignancies including NSCLC.
RED BLOOD CELL DISTRIBUTION WIDTH AND OUTCOMES IN FONTAN PATIENTS
Authors: Georges Ephrem, Amirhossein Esmaeeli, Jennifer Gerardin, Anita Saraf, Salim Hayek, Staci Jennings, Agasha Katabarwa, Fred Rodriguez, Arshed Quyyumi, Wendy Book
Journal: Journal of the American College of Cardiology (2017)
A randomized phase II trial of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: Gemcitabine alone vs. gemcitabine combined with cisplatin
Authors: D. H. Palmer, D. D. Stocken, J. A. C. Buckels, H. Hewitt, C. E. Markham, D. Mirza, P. J. Johnson, A. B. Hassan, S. R. Bramhall
Journal: Journal of Clinical Oncology (2004)

4215 Background: Overall 5 year survival for patients with pancreatic cancer is <1%, but with resectable disease ranges from 11%–24%. In units with an aggressive policy of surgical exploration, resection rates are only 50–60%. The greatest impact on survival will be achieved by increasing the resection rate. Preoperative chemotherapy may improve operability and therefore survival. Methods: 50 patients were randomized between 2 regimens of neoadjuvant therapy. 24 patients were randomized to gemcitabine (1000mg/m2) (G) every 7 days for 43 days. 26 patients were randomized to gemcitabine (1000mg/m2) and cisplatin (25mg/m2) (GC) every 7 days: 7 patients received an original schedule omitting day 22; due to neutropenia, the subsequent 19 patients received a revised schedule of GC omitting days 15 and 36. All patients had radiological and clinical evidence of pancreatic cancer considered resectable on CE-CT scan and were suitable for surgical exploration. Results: 22/24 G patients underwent treatment receiving a median (range) of 85% (71–100%) planned gemcitabine dose. 24/26 GC patients underwent treatment receiving a median (range) of 88% (40–109%) and 92% (40–100%) planned gemcitabine and cisplatin doses respectively. Grade III/IV hematological toxicity was experienced by 9 patients in each group. 27 (54%) patients underwent pancreatic resection: 9 (38%) G, of whom 7 had adenocarcinoma, 1 other carcinoma and 1 non-malignant; 18 (69%) GC, of whom 13 had adenocarcinoma, 3 other carcinomas and 2 non-malignant. 18 patients had a bypass procedure (14 G, 4 GC), and 5 patients had no surgery due to progressive disease (1 G, 4 GC). To date, 30 (60%) patients have died. 12-month survival from randomization was 46% and 61% for G and GC respectively. Conclusions: Neoadjuvant chemotherapy can be safely administered prior to pancreatic surgery. Combination therapy with gemcitabine and cisplatin appears more efficacious than gemcitabine alone in pancreatic cancer. A phase III trial of neoadjuvant GC vs. immediate surgery is planned. No significant financial relationships to disclose.
First-line cisplatin-fractionated doublet for unfit patients with advanced/metastatic non-small cell lung cancer.
Authors: Giovanni Mansueto, Filomena Narducci, Silvia Quadrini, Maria Laura Mancini, Isabella Sperduti, Teresa Gamucci
Journal: Journal of Clinical Oncology (2012)

e18072 Background: standard treatment for unfit patients (pts) with stage IIIB-IV non-small cell lung cancer (NSCLC) is single-agent chemotherapy. Such pts are usually not suitable for cisplatin (CDDP)-based chemotherapy due to poor performance status (PS) and/or significant comorbidity that could enhance toxicity of high-dose CDDP. They also are not able to tolerate hydric load that is recommended for CDDP at high doses. We investigated a schedule of fractionated CDDP as first-line treatment in unfit pts with stage IIIB/IV NSCLC. Methods: 42 consecutive unfit pts with advanced/metastatic NSCLC were treated. They all had ECOG PS 2 and/or significant comorbidity and were not eligible for a standard CDDP-based doublet. Median age was 65,6 years (range 46-77), stage IIIB/IV=15/27 pts. Histology: squamous 62,4%, adenocarcinoma 37,5%, other/NOS 0,1%. All pts received q3w CDDP 35 mg/mq d1-8 plus Gemcitabine 1000 mg/mq d1-8 or Pemetrexed 500 mg/mq d1 according to histology, for a maximum of 6 cycles. Maintenance Pemetrexed was allowed in pts with non-squamous histology. Progression-free survival (PFS), clinical benefit rate (CBR) and toxicity were evaluated. Results: 33 pts are evaluable for efficacy and 35 for toxicity. Mean number of cycles per patient was 5,03 (total 211). Maintenance with q3w Pemetrexed was performed in 10 pts (23,8%)(mean 4,3 cycles per patient). Five pts in response after CDDP received thoracic RT. A partial response was observed in 42,5% of pts and a stable disease in 35,4% of pts, for an overall CBR of 77,9%. Median PFS was 10,1 months (Kaplan-Meier); 31,9% of pts were progression-free at 1 year. Pts with adenocarcinoma had significantly better PFS than those with squamous histology (11 vs 8 months, p=0.03). G3-G4 haematological toxicity: neutropenia 48,4% (3% febrile), thrombocytopenia 27,2% and anaemia 9,0%. A 25% dose reduction was required in 39,3% of patients. One patient died for cardiac failure during treatment. Conclusions: fractionated CDDP seems to be effective in our patients population with advanced NSCLC. Adequate supportive care help to manage severe hematological toxicity. A randomized phase II trial of fractionated CDDP-doublet versus monotherapy has been planned.
VARIABILITY IN LEFT VENTRICULAR EJECTION FRACTION BY RADIONUCLIDE MULTIGATED ACQUISITION SCAN VERSUS ECHOCARDIOGRAPHY: IMPLICATIONS FOR PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
Authors: Edlira Yzeiraj, Amr F. Barakat, Paul Cremer, Wael Jaber
Journal: Journal of the American College of Cardiology (2017)
COMPARISON OF CLINICAL OUTCOMES: BIVALIRUDIN WITH TRANSFEMORAL VERSUS HEPARIN WITH TRANSRADIAL IN PATIENTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Jaya Reddy Mallidi, Muhammad Shakoor, Jane Garb, Daniel Fisher, Kurt Barringhaus, Amir Lotfi
Journal: Journal of the American College of Cardiology (2017)
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PROTEIN EXPRESSION IS INCREASED IN LIPID RICH HUMAN ATHEROSCLEROTIC PLAQUES COMPARED TO FIBROUS PLAQUES
Authors: Purushothaman K-Raman, Meerarani Purushothaman, Prakash Krishnan, Usman Baber, Urooz Zafar, Annapoorna Kini, Samin Sharma, Juan Badimon, Valentin Fuster, Pedro Moreno
Journal: Journal of the American College of Cardiology (2017)
Role of (18) F-FDG PET scanning in detecting osseous metastases in non-small cell lung cancer (NSCLC) in a community setting: A retrospective data analysis
Authors: S. R. Pulagam, J. Johnson, K. Nelson, B. Kim, L. Kirchner, E. Mamounas
Journal: Journal of Clinical Oncology (2006)

17067 Background: Metastasis from a distant site is the most common neoplastic process involving bone. Accurate staging of NSCLC is critical for effective management. Bone scans have been traditionally used for diagnosing bone metastases in NSCLC. Recently, PET scanning has been shown to be effective in detecting bone metastases in several studies. In NSCLC, using a single PET scan to evaluate both the primary tumor and bone metastases might be more cost-effective and if the accuracy of PET scanning for detection of bone metastases can be established, the need for bone scanning may be obviated. We performed a retrospective comparison between PET scan and bone scan in NSCLC patients diagnosed and treated in a community hospital setting. Methods: 50 patients who were diagnosed with NSCLC between January 1, 2002 and December 31, 2004 and who had both PET scan and Bone scan done within 3 months of each other were included in the study. 47 patients had both investigations within 40 days duration. Data regarding all the lesions found on bone and PET scan were collected. Results: The median age of the patients was 70.5 years. Total of 20 patients were diagnosed with bone metastases by one or the other test. Of these 15 were identified with bone scan with a sensitivity of 75% (95% Confidence interval CI 56.2%–97.1%). 17 patients were identified by PET scan with a sensitivity of 85% (95% CI 45.5%–92%), p-value -0.48 compared to bone scan. 3 patients who had positive bone scan had a negative PET scan. 5 patients who had positive PET scan had a negative bone scan. Conclusions: PET scan appears to be as good as bone scan in detecting bone metastases. Unless very high clinical suspicion exists regarding bone metastases, negative PET-Scan for bone metastases should obviate the need for bone scan. [Table: see text] No significant financial relationships to disclose.
IMPACT OF AORTIC VALVE CALCIFICATION AND SEX ON HEMODYNAMIC PROGRESSION AND CLINICAL OUTCOMES IN AORTIC STENOSIS
Authors: Lionel Lloyd Tastet, Maurice Enriquez-Sarano, Romain Capoulade, Youssef Maalouf, Philip Araoz, Louis Simard, Mylène Shen, Hector Michelena, Eric Larose, Marie Arsenault, Élisabeth Bédard, Jordan Miller, Philippe Pibarot, Marie-Annick Clavel
Journal: Journal of the American College of Cardiology (2017)